Hypoglycemia and weight gain are the primary complications of insulin therapy in T1D, which are dose-dependent.32,33 The results of previous clinical trials and those of our study suggested that SGLT-2 inhibitors contribute to the reduction of the total daily insulin dose which seems to be a promising finding.1,14,21,27 Based on empagliflozin’s insulin-independent mechanism of action, hypoglycemia events were not observed which is similar to the results of a previous trial by Pieber et al, who evaluated the effectiveness and safety of empagliflozin in patients with T1D during a 4-week study. This evidence concerns the gene SLC5A2 and type 1 diabetes mellitus.